Literature DB >> 26790445

The inconsistency of molecular subtypes between primary foci and metastatic axillary lymph nodes in Luminal A breast cancer patients among Chinese women, an indication for chemotherapy?

Yadong Sun1,2, Xiaofeng Liu3, Shude Cui2, Lianfang Li2, Peiqi Tian2, Shanqing Liu2, Yong Li2, Mengmeng Yin2, Chongjian Zhang2, Qixin Mao2, Jiaxiang Wang4.   

Abstract

Patients with Luminal A breast cancer often have favorable prognosis, but some of these patients still have lymph node metastases, it remains unclear what the role of adjuvant chemotherapy is in Luminal A subtype with lymph node metastases. The aim of this study was to find a new method to distinguish which Luminal A patient can be benefited from chemotherapy. We retrospectively investigated the inconsistency of molecular subtypes between primary foci and metastatic axillary lymph nodes in Luminal A breast cancer patients, and analyzed the clinicopathologic characteristics, Recurrence score (RS), disease-free survival (DFS), and overall survival (OS) in 146 Luminal A breast cancer patients. The discordance of molecular subtypes between primary foci and metastatic lymph nodes were explored by univariate and multivariate logistic regression. The DFS and OS were calculated by the Kaplan-Meier survival curves, and the Cox regression analyses were performed to identify independent prognostic factors for DFS and OS. In our results, the inconsistency was found in 55 patients (55/146, 37.67 %). Lymphatic vascular invasion (OR 6.402, 95 % CI 2.371-17.287, P < 0.001), lymph node stage (OR 2.147, 95 % CI 1.095-4.209, P = 0.026), and histological grade (OR 3.319, 95 % CI 1.101-8.951, P = 0.032) were significantly related to the inconsistency. The inconsistent group (non-Luminal A variations) had a poor prognosis compared with the consistent group, the DFS between the two groups was significantly different (P = 0.022), but the OS did not have obvious difference (P = 0.140). Moreover, the inconsistency was associated with high RS (P = 0.036). In conclusion, more aggressive molecular subtypes in metastatic lymph nodes, which associated with poor prognosis, were observed in Luminal A breast cancer patients, which indicate that chemotherapy is necessary for these patients.

Entities:  

Keywords:  Breast cancer; Luminal A; Lymph node metastases; Molecular subtype

Mesh:

Substances:

Year:  2016        PMID: 26790445     DOI: 10.1007/s13277-016-4844-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  16 in total

1.  Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.

Authors:  Gong Tang; Steven Shak; Soonmyung Paik; Stewart J Anderson; Joseph P Costantino; Charles E Geyer; Eleftherios P Mamounas; D Lawrence Wickerham; Norman Wolmark
Journal:  Breast Cancer Res Treat       Date:  2011-01-11       Impact factor: 4.872

2.  Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.

Authors:  Anna-Karin Falck; Pär-Ola Bendahl; Gunilla Chebil; Hans Olsson; Mårten Fernö; Lisa Rydén
Journal:  Breast Cancer Res Treat       Date:  2013-06-27       Impact factor: 4.872

3.  Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor.

Authors:  Robyn Macfarlane; Melanie Seal; Caroline Speers; Ryan Woods; Hamad Masoudi; Samuel Aparicio; Stephen K Chia
Journal:  Oncologist       Date:  2012-01-20

4.  Gene expression profiling for breast cancer prognosis in Chinese populations.

Authors:  Bing Sun; Feng Zhang; Shi-Kai Wu; Xiaohong Guo; Li-Li Zhang; Ze-Fei Jiang; Duen-Mei Wang; San-Tai Song
Journal:  Breast J       Date:  2011 Mar-Apr       Impact factor: 2.431

5.  Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases.

Authors:  Lurdes Torres; Franclim R Ribeiro; Nikos Pandis; Johan A Andersen; Sverre Heim; Manuel R Teixeira
Journal:  Breast Cancer Res Treat       Date:  2006-08-09       Impact factor: 4.872

6.  The prognostic value of lymph node ratio in node-positive breast cancer: a Dutch nationwide population-based study.

Authors:  Pim J M Dings; Marloes A G Elferink; Luc J A Strobbe; Johannes H W de Wilt
Journal:  Ann Surg Oncol       Date:  2013-03-28       Impact factor: 5.344

7.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.

Authors:  C W Elston; I O Ellis
Journal:  Histopathology       Date:  1991-11       Impact factor: 5.087

8.  Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.

Authors:  A Goldhirsch; W C Wood; A S Coates; R D Gelber; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2011-06-27       Impact factor: 32.976

9.  Variability of oestrogen and progesterone receptor status between primary breast cancer and nodal metastases: preliminary communication.

Authors:  D Fernandez; P Sauven; J Alaghband-Zadeh; J I Burn
Journal:  J R Soc Med       Date:  1982-09       Impact factor: 18.000

10.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

Authors:  A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2013-08-04       Impact factor: 32.976

View more
  4 in total

Review 1.  Lymph Nodes in Breast Cancer - What Can We Learn from Translational Research?

Authors:  Florentia Peintinger; Roland Reitsamer; Marjolein L Smidt; Thorsten Kühn; Cornelia Liedtke
Journal:  Breast Care (Basel)       Date:  2018-09-25       Impact factor: 2.860

2.  Tumor size estimation of the breast cancer molecular subtypes using imaging techniques.

Authors:  Gulten Sezgın; Melda Apaydın; Demet Etıt; Murat Kemal Atahan
Journal:  Med Pharm Rep       Date:  2020-07-22

Review 3.  Efficacy of chemotherapy for lymph node-positive luminal A subtype breast cancer patients: an updated meta-analysis.

Authors:  Yilun Li; Li Ma
Journal:  World J Surg Oncol       Date:  2020-12-02       Impact factor: 2.754

4.  Heterogeneity between Core Needle Biopsy and Synchronous Axillary Lymph Node Metastases in Early Breast Cancer Patients-A Comparison of HER2, Estrogen and Progesterone Receptor Expression Profiles during Primary Treatment Regime.

Authors:  Laura Weydandt; Ivonne Nel; Anne Kreklau; Lars-Christian Horn; Bahriye Aktas
Journal:  Cancers (Basel)       Date:  2022-04-07       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.